49 citations
,
February 2022 in “Drug Design Development and Therapy” Ritlecitinib shows promise for hair regrowth in alopecia areata patients.
57 citations
,
April 2009 in “The Journal of Steroid Biochemistry and Molecular Biology” Steroidogenesis inhibitors change but don't stop androgen production in prostate cancer.
April 2026 in “Frontiers in Medicine” Enfortumab vedotin can cause skin issues, especially in older males, needing early monitoring.
October 2025 in “Zenodo (CERN European Organization for Nuclear Research)” Ritlecitinib may help young adults with severe alopecia areata when ketoconazole fails.
January 2025 in “Scholarly Commons (University of Pennsylvania)” UTX is important for skin health and its loss can lead to skin issues, especially in females.
December 2023 in “bioRxiv (Cold Spring Harbor Laboratory)” The research suggests Dutasteride and Solifenacin may be effective against the bacterium causing listeriosis.
2 citations
,
March 2026 in “Journal of Dermatological Treatment” JAK inhibitors for alopecia areata have different safety risks, requiring specific monitoring for each drug.
2 citations
,
January 2011 Researchers developed a quick and accurate method to measure finasteride and tamsulosin in tablets.
December 2020 in “Skin appendage disorders” Finasteride may effectively treat hair loss in Klinefelter Syndrome patients.
5 citations
,
September 2015 in “Medical hypotheses” Topical sulfonylurea may reduce excessive hair growth caused by certain medications.
September 2024 in “Annals of Medicine and Surgery” Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.
1 citations
,
March 2026 in “American Journal of Clinical Dermatology” Ritlecitinib effectively regrows hair in severe alopecia areata, especially in adolescents.
13 citations
,
January 2020 in “Acta Dermato Venereologica” Ruxolitinib treatment led to unexpected hair regrowth in a patient with alopecia universalis.
October 2021 in “Meditsinskiy sovet = Medical Council” Cyproterone acetate improves skin symptoms and quality of life in women with androgen-related issues.
March 2024 in “Frontiers in endocrinology” A new MTX2 gene mutation caused a severe genetic disorder in a young Chinese girl.
December 2025 in “The Journal of Dermatology” Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.
December 2025 in “Actas Dermo-Sifiliográficas” Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.
14 citations
,
May 2022 in “International Journal of Molecular Sciences” Platelet-rich plasma improves bladder function and reduces overactivity in ketamine-induced bladder issues.
10 citations
,
July 2011 in “Archives of Pharmacal Research” 68 citations
,
January 2013 in “BMC Pharmacology and Toxicology” Glibenclamide slows breast cancer cell growth by stopping cell division.
January 2025 in “Annals of Dermatology” New treatments for hair loss include low-dose oral minoxidil, light therapy, and innovative therapies targeting hair growth mechanisms.
January 2016 in “The Australian Pharmacist” Tofacitinib might be used to treat hair loss.
13 citations
,
August 2013 in “Journal of pharmaceutical sciences” Researchers created a skin patch that delivers two drugs for treating enlarged prostate, which may improve patient use and dosage control.
11 citations
,
April 2021 in “Advanced synthesis & catalysis” PXX is an effective and affordable photocatalyst for creating new chemical bonds in organic synthesis.
1 citations
,
July 2020 in “Reviews in separation sciences” April 2014 in “The FASEB Journal” Testosterone reduces knee movement, while flutamide and finasteride increase it.
15 citations
,
June 2012 in “British Journal of Dermatology” A new mutation in the KRT86 gene causes a hair disorder with variable expression.
108 citations
,
January 2003 in “Fertility and Sterility” Flutamide may slightly improve hair loss in women, but finasteride does not work.
January 2019 in “Oncogen” Triple Hormonal Blockade (ADT3) can effectively manage prostate cancer but requires careful monitoring for heart risks.
December 2023 in “Journal of clinical medicine” Some leukemia treatments can cause skin reactions similar to keratosis pilaris.